レボドーパ誘発性ディスキネジアの流行病学: ラテンアメリカにおける流行および関連する臨床的要因
medRxiv : the preprint server for health sciences
|September 5, 2025
まとめ
ラテンアメリカにおけるパーキンソン病患者の25.4%がレボドーパ誘発性運動障害 (LID) に罹患しており,その罹患率は国によって異なります. 病気の急速な進行はLIDと関連しているが,性別は関係なく,地域特有の研究の必要性を強調している.
科学分野:
- 神経学
- 流行病学
- 遺伝学
背景:
- レボドパはパーキンソン病 (PD) の主要な治療法ですが,慢性使用はレボドパ誘発性運動障害 (LID) を引き起こします.
- LIDはPDの予後,生活の質,医療費に大きな影響を及ぼします.
- LIDの危険因子に関する既存の研究は主にヨーロッパ系の子孫の集団を対象としています.
研究 の 目的:
- ラテンアメリカとカリブ海 (LATAM) の集団におけるLIDの流行を決定する.
- この多様な集団におけるLIDと既知のおよび新しい因子の関連性を評価する.
主な方法:
- パーキンソン病の遺伝学に関するラテンアメリカ研究コンソーシアム (LARGE-PD) のデータを活用した横断的な研究.
- LID状態とレボドーパ使用に関する情報を持つ8つのLATAM諸国から3695人のPD患者を含む.
- LIDに関連する要因を特定するために,ロジスティック回帰を含む統計分析.
主要な成果:
- LATAMコホートにおけるLIDの総発生率は25.4%で,国によって有意な差異がある (コロンビアでは9. 3%,プエルトリコでは45. 1%).
- LIDの流行は,病期が長くなるにつれて増加した.
- 病気の急速な進行はLID (OR: 1.55) と有意に関連していたが,性別はそうではなかった (OR: 1.02).
結論:
- この研究はLATAM地域におけるLIDの最も広範な疫学的な分析を表しています.
- LIDの既知の危険因子の中には,LATAMの集団において関連するものもあるが,性別などの危険因子には関係がないかもしれない.
- LIDのメカニズムを理解し,それに合わせて治療戦略を策定するために,集団特有の研究が不可欠であることを強調しています.
関連する概念動画
Parkinson's Disease: Treatment
375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
591
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
591
Factors Influencing Drug Absorption: Disease States and Pharmacology
762
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
762
Prevalence and Incidence
783
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
783
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
438
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
438


